NYSE: ABT · Medical Devices

Abbott Laboratories (ABT) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Abbott Laboratories (ABT) at $106.73 a share. The stock last closed at $107.45, which puts the model's fair value 0.7% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Abbott Laboratories.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$106.73midpoint of 2,000 simulations
Last close$107.45NYSE: ABT
Gap to fair value-0.7%fair value against price
Model verdictFairly valuedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 moved the fair value from $111.77 to $106.73 (-4.5%). The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move.

What the model makes of itThe price of $107.45 is 0.7% above it: Fairly valued, on a high evidence grade.

What's nextNext report on 28 Jan 2027. Options prices imply a move of about 8% either way over the next month. The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give ABT?

The calibrated range for ABT over 63 trading days is $97.94 to $118.43. It sits around the last close, and its width comes from the volatility that ABT's own options imply (28% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $87.88 to $127.39. In 46% of the simulations the fair value came out above the price the model ran on.

$69.33$160.65
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $106.73. Dashed line: the last close, $107.45.

Faircurve Insights · 14 Nov 2026

Abbott Laboratories is a global healthcare enterprise. It is dedicated to the research, development, manufacturing and worldwide distribution of a diverse portfolio of health solutions.

Faircurve's model put the fair value at $106.73 a share on 14 Nov 2026. The previous run, on 7 Nov 2026, gave $111.77, and the fair value moved -4.5%. The model's reason, in its own words: the model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move. The calibrated range over 63 trading days is $97.94 to $118.43, built around the price from the stock's own options-implied volatility. Ranges built this way held the price 60% of the time at this horizon, based on 8,038 past valuations refreshed 14 Nov 2026. The evidence grade is High. It does not say whether the fair value is right.

Abbott's overall quality score is 52 out of 100, measured against comparable companies. Stability scores 92: EBITDA margin downside volatility is 0.5 pts over five years, against a peer median of 1.6 pts. Earnings quality scores 82: FCF / net income is 1.44x, against a peer median of 1.26x. Profitability scores 22: ROIC is 6.6%, against a peer median of 11.7%. The comparable companies are Medtronic, Stryker, Boston Scientific, Edwards Lifesciences, GE HealthCare, DexCom and Zimmer Biomet.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does ABT report earnings, and how has the stock reacted?

Abbott Laboratories's next earnings report is scheduled for 28 Jan 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 3.9% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. ABT's 30 day implied volatility works out to about 8.1% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across ABT's last 8 reports, ignoring direction, was 5.1%.

0%5%10%15%3.8%5.5%22 Jan '254.9%3.8%16 Apr '254.0%6.1%17 Jul '254.3%4.2%15 Oct '254.5%11.0%22 Jan '265.6%4.7%16 Apr '266.3%12.8%16 Jul '267.0%0.1%21 Oct '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in ABT

0%5%10%15%21 Oct '26 report16 Jul '26 report16 Apr '26 report22 Jan '26 report8% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 6% on 14 Nov 2025, reached 10% on 10 Apr 2026 and reads 8% on 16 Nov 2026. The marks are report dates.

How does ABT score on business quality?

Abbott Laboratories's overall quality score is 52 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.226.6%ROIC11.7%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).821.44xFCF / net income1.26x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.615.7%Revenue growth, trailing10.1%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.380.8%Net buybacks / market value1.6%
Balance sheetNet debt to EBITDA and interest coverage.372.45xNet debt / EBITDA1.70x
StabilityDownside volatility of the EBITDA margin over the last five years.920.5 ptsEBITDA margin downside volatility, 5y1.6 pts

How does ABT compare with similar companies?

The companies in medical devices closest to Abbott Laboratories in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
MDT Medtronic Plc$102.88$100.47-2.3%Fairly valued
SYK Stryker Corporation$310.72$275.49-11.3%Fairly valued
BSX Boston Scientific Corporation$43.69$52.05+19.1%Undervalued
EW Edwards Lifesciences Corporation$107.11$88.12-17.7%Overvalued
GEHC GE HealthCare Technologies Inc.$82.96$90.14+8.7%Fairly valued
DXCM DexCom, Inc.$81.61$73.84-9.5%Fairly valued
ZBH Zimmer Biomet Holdings, Inc.$101.41$120.99+19.3%Undervalued
GKOS Glaukos Corporation$244.88$228.07-6.9%Data under review

What the comparable companies' multiples alone would give for ABT, the peer-implied price, is $103.66 a share on this run. The fair value weighs that against the company's own multiple.

All medical device stocks ranked by gap to fair value

Abbott Laboratories at a glance

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions.

Market value
$188.0B
Sector
Healthcare
Industry
Medical Devices
Revenue expected, next twelve months
$53.2B
Consensus revenue growth, next fiscal year
+12.8%
Analysts with estimates
17
Beta to the US market
-0.03
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. ABT was not among them.

How the fair value is worked out: the model prices Abbott Laboratories on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for ABT was $111.77. As of 14 Nov 2026 it is $106.73, a change of -4.5%. The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Abbott Laboratories's valuation

Is Abbott Laboratories stock undervalued or overvalued?

On Faircurve's model, ABT reads as Fairly valued as of 14 Nov 2026. The model's fair value is $106.73 a share against a last close of $107.45, a gap of -0.7%.

What is ABT's fair value?

$106.73 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $87.88 to $127.39.

What price range does the model give ABT?

$97.94 to $118.43 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Abbott Laboratories report earnings next?

The next report is scheduled for 28 Jan 2027. Companies can move their dates.

How much has ABT moved on past earnings reports?

Across its last 8 reports the median two session move was 5.1%, ignoring direction. The largest was +12.8% around the report of 16 Jul 2026.

How confident is the model in this valuation?

The model's evidence grade for ABT is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on ABT

The model holds no idea open on ABT today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on ABT with their outcomes. A free account is enough.

Keep reading